NCT05311618 - Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 11, 2022

Primary Completion Date

April 30, 2025

Study Completion Date

June 30, 2025

Conditions

Pancreatic CancerBreast CancerGastric CancerNon Small Cell Lung CancerCervical CancerEndocervical CancerSquamous Cell Carcinoma of Head and NeckBladder Urothelial CancerColorectal CancerEsophageal CancerOvarian CancerRenal Cell CarcinomaProstate CancerMelanomaMesotheliomaCholangiocarcinoma

Interventions

DRUG

NGM438

NGM438 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.

DRUG

Pembrolizumab (KEYTRUDA ®)

Pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21 day cycle.

Trial Locations (6)

10029

Mount Sinai Hospital, New York

48202

Henry Ford Health System, Detroit

49546

START Midwest, Grand Rapids

77030

MD Anderson, Houston

80218

SCRI Denver, Denver

06520

Yale Cancer Center, New Haven